Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 353-358

  Xiang, Jim ^a,c   Qi, Yumin ^a   Chen, Yue ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Anti TAG72 antibody; Recombinant fusion protein; Tumor inhibition; Tumor necrosis factor

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; RM4 TNF PROTEIN, RECOMBINANT; RM4-TNF PROTEIN, RECOMBINANT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL DIVISION; CELL LINE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; ISOGRAFT; LYMPHOCYTE DEPLETION; METHODOLOGY; MOUSE; MULTIPLE MYELOMA; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CELL DIVISION; CELL LINE; GENE THERAPY; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSFECTION; TRANSPLANTATION, ISOGENEIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031266012     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Carswell E, Old J, Kassel R, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666-3670.
2. Philip R, Epstein L. Tumor necrosis factor as immuno-modulator and mediator of monocyte toxicity induced by itself, gamma-interferon and interleukin-1. Nature. 1986; 323:86-89.
3. Talmadge J, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res. 1988;48:544-550.
4. Shalaby M, Aggarwal B, Rinderknecht E, et al. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. J Immunol. 1985;135:2069-2073.
5. Ranges G, Figari I, Espevic T, Palladino M. Inhibition of cytotoxic T cell development by transforming growth factor-beta and reversal by recombinant tumor necrosis factor-alpha. J Exp Med. 1987;166:991-998.
6. Robinet E, Branelec D, Termijtelen A, et al. Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T cells. J Immunol. 1990;144:4555-4561.
7. Creasey A, Reynolds M, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res. 1986;46:5687-5690.
8. Asher A, Mule J, Reichert C, Shiloni E, Rosenberg S. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963-974.
9. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1986;6:1328-1334.
10. Moritz T, Niederle N, Baumann J, et al. Phase I study of recombinant human tumor necrosis factor áin advanced malignant disease. Cancer Immunol Immunother. 1989;29: 144-149.
11. Sherman M, Spriggs D, Arthur K, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344-354.
12. Spriggs D, Sherman M, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24 hour intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst. 1988;80:1039-1044.
13. Creaven P, Plager J, Dupere S, et al. Phase-I clinical trial of recombinant human necrosis factor. Cancer Chemother Pharmacol 1987;20:137-144.
14. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
15. Asher A, Mule J, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor. J Immunol. 1991;146:3227-3234.
16. 2 and tumor necrosis factor. J Biotech. 53:3-12, 1997.
17. Xiang J, Moyana T, Karla J, Hamilton T, Qi Y. Construction and characterization of a high-affinity chimeric anticolorectal carcinoma antibody ccM4. Mol Biother. 1992;4: 174-183.
18. Qi Y, Moyana T, Chen Y, Xiang J. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-τ. Hum Antib Hybrid. 1996;7:21-26.
19. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-τ elicits anti-tumor CD8 MHC class I-restricted T cells that are cytotoxic in vitro and tumoricidal in vivo. J Interferon Cytokine Res. 1996;16:771-776.
20. Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J Exp Med. 1991;173:1047-1052.
21. Fujii M, Liu Y, Neda H, et al. Augmented systemic immunity in mice implanted with tumor necrosis factor gene-transduced Meth-A cells. Jpn J Cancer Res. 1994;85: 315-324.
22. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
23. Chen L, Ashe S, Brady W, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
24. Teng M, Park B, Koeppen H, et al. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA. 1991;88:3535-3539.
25. Allione A, Consalvo M, Manni P, et al. Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GMCSF, and IFN gene or admixed with conventional adjuvants. Cancer Res. 1994;54: 6022-6026.
26. Golumbeck P, Lazenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin 4. Science. 1991;254:713-716.
27. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
28. Katsanis E, Orchard P, Bausero M, et al. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother. 1994;15:81-90.
29. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
30. Porgador A, Bennerji R, Watanable Y, et al. Anti-metastatic vaccination of tumor-bearing mice with two types of IFN gene-inserted tumor cells. J Immunol. 1993;150:1458-1470.
31. Kimura A, Xiang J. High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants. J Natl Cancer Inst. 1986; 76:1247-1254.